Dive into the archives.
- Elan and Biogen are in a Fight
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging [...]
- Biogen Says Eighth Patient Has Infection From Tysabri
By Tom Randall
June 12 (Bloomberg) — Biogen Idec said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.
The patient was confirmed to have progressive multifocal leukoencephalopathy, or PML, on June 10, according to a report on Cambridge, Massachusetts-based Biogen’s Web site. [...]
- Hot off the AAN Press: Fingolimod effective but safety an issue
UPDATE 3-Novartis MS drug effective but safety an issue
ZURICH, April 29 (Reuters) – Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a [...]
- Hot off the AAN Press: Tysabri May Reverse MS Damage
UPDATE 1-Elan’s Tysabri may reverse MS damage, shares up
April 29 (Reuters) – Elan’s Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec said on Wednesday, boosting Elan’s shares 10 percent.
Data released by the companies at the American Academy of Neurology showed Tysabri promoted [...]
- Malaria Pill=The End of PML?
Elan shares soar on news of possible Tysabri side-effect treatment
SHARES IN drug company Elan bounced more than 10 per cent yesterday after news emerged of a possible treatment for a potentially fatal side effect of its multiple sclerosis therapy, Tysabri.
Biogen Idec, Elan’s partner in the development and sale of Tysabri, is testing the efficacy of [...]
